American Shared Hospital Services (AMS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Revenue grew 15.9% year-over-year to $7.1 million, driven by expansion in direct patient services and higher procedure volumes at Rhode Island and Puebla centers.
Gross margin increased 36.7% year-over-year to $1.3 million, or 18.2% of revenue, reflecting improved utilization and higher revenue.
Net loss attributable to shareholders was $0.6 million ($0.09/share), a slight improvement from $0.10/share in Q1 2025, due to increased revenues offset by higher operating costs.
Adjusted EBITDA rose 18.4% year-over-year to $1.1 million, reflecting improved operating performance.
Leadership transition announced with Craig Tagawa appointed as interim CEO, bringing over 35 years of experience.
Financial highlights
Total revenue: $7.1 million, up from $6.1 million in Q1 2025, led by direct patient services.
Gross margin: $1.3 million (18.2% of revenue), up from $0.9 million (15.4%).
Operating loss narrowed to $0.9 million from $1.3 million year-over-year.
Cash and equivalents increased to $5.2 million from $3.7 million at year-end.
Net loss per share was $0.09, compared to $0.10 in Q1 2025.
Outlook and guidance
Volumes are trending higher into Q2 2026, with continued growth expected in direct patient care and proton therapy.
Management is focused on optimizing operations, increasing patient access, and enhancing financial performance.
New facilities in Rhode Island (Bristol and Johnston) on schedule, with openings expected in 18–30 months.
Guadalajara center expected to begin operations late 2026.
Management is actively negotiating with lenders to extend or amend credit agreements but cannot assure successful outcomes.
Latest events from American Shared Hospital Services
- Audit fee disclosures for 2024 were corrected; prior proxy votes remain valid unless changed.AMS
Proxy filing7 May 2026 - Virtual vote set for June 24, 2026, on directors, pay, incentive plan, and auditor ratification.AMS
Proxy filing30 Apr 2026 - Virtual meeting to vote on directors, executive pay, incentive plan, and auditor ratification.AMS
Proxy filing30 Apr 2026 - 2025 revenue was $28.1M with a net loss of $1.6M amid a shift to direct patient care.AMS
Q4 202531 Mar 2026 - Q2 2024 net income surged to $3.6M on 27% revenue growth and a major acquisition gain.AMS
Q2 20241 Feb 2026 - Q3 revenue rose 36.3% to $6.99M, but margins fell on higher costs and lower Gamma Knife volumes.AMS
Q3 202414 Jan 2026 - Strong FY 2024 growth led by direct patient services and international expansion.AMS
Q4 202425 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and governance, with focus on diversity.AMS
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor ratification June 26, 2025.AMS
Proxy Filing2 Dec 2025